New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
2025-09-09
(Press-News.org) (Barcelona, Spain September 9, 2025 1 p.m. CEST / UTC +2) — New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.
The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
SCLC tumors are typically characterized by low expression of major histocompatibility complex class I (MHC-I), which impairs immune recognition and response. Researchers from the Shanghai Pulmonary Hospital and the University of Pittsburgh have discovered that IFITM3 enhances MHC-I expression by activating NLRC5, a key transcriptional regulator, and promoting its nuclear translocation. This effect improves antigen presentation and boosts CD8⁺ T cell infiltration and cytotoxicity.
“Our study shows that IFITM3 plays a pivotal role in shaping tumor immunogenicity in SCLC,” said Dr. Xinyu Liu of Shanghai Pulmonary Hospital, Tongji University School of Medicine, China. “It may serve both as a predictive biomarker for immunotherapy response and a novel therapeutic target.”
Dr. Liu presented a number of significant findings:
Strong correlation between IFITM3 and MHC-I expression in multiple real-world SCLC cohorts.
IFITM3 overexpression upregulated antigen presentation pathways and increased CD8⁺ T cell infiltration.
IFITM3 expression predicted improved progression-free survival in patients receiving chemoimmunotherapy.
A novel compound, ethyl gallate (EG), induced IFITM3 and sensitized tumors to PD-1 blockade in preclinical models.
“Our study suggests that pharmacological induction of IFITM3 could represent a new strategy to improve clinical outcomes for patients with SCLC. Future clinical research may validate IFITM3 as both a biomarker and a therapeutic adjunct to current immunotherapy regimens,” Dr. Liu reported.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-09-09
Birds flock in order to forage and move more efficiently. Fish school to avoid predators. And bees swarm to reproduce. Recent advances in artificial intelligence have sought to mimic these natural behaviors as a way to potentially improve search-and-rescue operations or to identify areas of wildfire spread over vast areas—largely through coordinated drone or robotic movements. However, developing a means to control and utilize this type of AI—or “swarm intelligence”—has proved challenging.
In a newly published paper, an international team of scientists describes a framework designed to advance swarm intelligence—by controlling flocking and ...
2025-09-09
(Barcelona, Spain--September 9, 2025 at 11:30 AM CEST / UTC +2)— A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).
The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on Lung Cancer (WCLC).
In the fully enrolled Cohort 5 of the PALOMA-2 trial, the Q4W dosing regimen was shown to maintain similar efficacy compared ...
2025-09-09
A study led by University of Oxford and Brookhaven National Laboratory researchers has uncovered how exposure to hydrogen atoms dynamically alters the internal structure of stainless steel.
The findings reveal that hydrogen allows internal defects in steel to move in ways not normally possible – which can lead to unexpected failure.
This discovery offers vital insights that could help make hydrogen fuel systems safer and more reliable, from aircraft and fusion reactors to pipelines and storage tanks.
The study has been published today (9 Sept) ...
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
The research, led by scientists at the National Cancer Center of China, assessed ctDNA in 177 patients with LS-SCLC treated with chemoradiotherapy (CCRT), 77 of whom received consolidation immune checkpoint inhibitors (ICIs). Circulating tumor DNA was measured ...
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) – A new study presented today reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).
The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
The phase 2a clinical trial investigated the efficacy of two intratumoral injections of CAN-2409 combined with an oral prodrug (valacyclovir) in ...
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The trial, which enrolled both oligometastatic and polymetastatic patients, is the first to assess surgical ...
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.
The research was reported at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study, based on 2,040 valid survey responses from 34 WHO European Region countries in 20 languages, evaluated three key areas: general knowledge about lung cancer, access to information, ...
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.
The study results were reported today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
FANSS is the first known lung cancer screening program in the U.S. dedicated exclusively to ...
2025-09-09
Five well-publicized polar geoengineering ideas are highly unlikely to help the polar regions and could harm ecosystems, communities, international relations, and our chances of reaching net zero by 2050.
This is according to a new assessment, published in Frontiers in Science, which looked at five of the most developed geoengineering proposals currently being considered for use in Antarctica and the Arctic.
The polar regions are home to fragile communities and ecosystems, as well as most of the world’s ice. Technological ‘geoengineering’ approaches have been proposed to delay or address the impacts of climate ...
2025-09-09
Unarmed Black civilians are three times more likely to be shot and killed by police officers than unarmed white civilians in the U.S. In tragic cases in recent years, unarmed Black men holding innocuous objects like a wallet, cell phone, or vape pen were killed by police officers because those objects were misidentified as weapons. These split-second fatal mistakes, often under ambiguous and stressful conditions, have sparked urgent debates about their causes and how to fix them.
A new brain-imaging study from researchers at Columbia University ...
LAST 30 PRESS RELEASES:
[Press-News.org] New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
